Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bossuyt

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Gut|August 12, 2024
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximabNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Gastroenterology|June 9, 2019
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's DiseaseMark Löwenberg, Severine Vermeire, Nahid Mostafavi, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Autoimmunity Reviews|May 11, 2021
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensusFerdinando D'Amico, Virginia Solitano, Daniel Aletaha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 2, 2019
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's DiseaseChristopher Ma, Krisztina B Gecse, Marjolijn Duijvestein, et al.
Journal of Crohn'S & Colitis|November 7, 2023
Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological OutcomesSéverine Vermeire, Jurij Hanzel, Mark Löwenberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 29, 2020
High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled TrialJessica R de Bruyn, Peter Bossuyt, Marc Ferrante, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2025
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapyEdouard Louis, Peter Bossuyt, Arnaud Colard, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Gut|August 12, 2024
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximabNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Gastroenterology|June 9, 2019
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's DiseaseMark Löwenberg, Severine Vermeire, Nahid Mostafavi, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Autoimmunity Reviews|May 11, 2021
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensusFerdinando D'Amico, Virginia Solitano, Daniel Aletaha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 2, 2019
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's DiseaseChristopher Ma, Krisztina B Gecse, Marjolijn Duijvestein, et al.
Journal of Crohn'S & Colitis|November 7, 2023
Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological OutcomesSéverine Vermeire, Jurij Hanzel, Mark Löwenberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 29, 2020
High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled TrialJessica R de Bruyn, Peter Bossuyt, Marc Ferrante, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2025
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapyEdouard Louis, Peter Bossuyt, Arnaud Colard, et al.
Pageof 14